We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks

News   Mar 25, 2014

 
Ferrer Licenses Commercialization Rights for Ozenoxacin in US to Medimetriks
 
 
Advertisement
 

RELATED ARTICLES

Rewriting the Rules of Vaccine Design With DNA Origami

News

By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune response from human immune cells grown in a lab dish. Such particles might eventually be used as an HIV vaccine.

READ MORE

Combination Therapy Improves Survival Rates for Women With Aggressive Endometrial Cancer in Phase 2 Trial

News

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

READ MORE

Clinical Trial Investigates Alpha-1-Antitrypsin for Severe COVID-19 Infection

News

Clinician scientists at RCSI University of Medicine and Health Sciences have begun a trial investigating alpha-1-antitrypsin as a treatment for critically ill patients mechanically ventilated in ICU with COVID-19 associated acute respiratory distress syndrome.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE